NextVivo is a biotechnology company developing an immune organoid platform to transform the future of drug development. NextVivo’s organoids are miniature 3D cell cultures that model the composition, structure, and function of human tissue and can uniquely recapitulate the humoral and cellular immune response outside of the body. By leveraging this technology, NextVivo can generate fully human cell and antibody candidate therapies by leveraging the immune system’s natural defenses, with an initial focus on oncology and autoimmune indications. Further, NextVivo’s organoids allow the company to efficiently test pre-clinical candidates on ex vivo human tissue models and identify the most effective therapies for clinical development. The company was co-founded by Drs. Mark Davis and Calvin Kuo from Stanford University, and by Dr. Adam Margolin, Venture Partner at Khosla Ventures and former Chair and Professor of Genetics and Genomic Science and Senior Associate Dean at Mount Sinai.